This bill requires the Food and Drug Administration to solicit public comment on factors that should be taken into account when considering proposed modifications to approved risk evaluation and mitigation strategies for drugs. The Government Accountability Office must report on the number of proposed modifications that have been granted and the related effects on patient access or provider administration with respect to such drugs.
Action Date | Type | Text | Source |
---|---|---|---|
2022-05-03 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
2022-05-03 | IntroReferral | Introduced in House | Library of Congress |